Drug intelligence / Profile preview

SOL-410

Development stage: Preclinical
Lead developer: Sola Biosciences
Modality: Gene Therapies

Overview

SOL-410 is a gene therapy candidate developed by SOLA Biosciences for the treatment of nervous system diseases, with active indications including Alzheimer disease and frontotemporal dementia. Its mechanism of action is based on gene therapy, but specific genetic targets or vectors have not been disclosed in available sources. The drug is currently in preclinical development and has not received any regulatory approvals[1][2][3].

Other names: SOL-410SOL410SOL 410

Beyond the preview

Go deeper on SOL-410.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-410.

Explore the full profile